The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

The S&P 500 and Nasdaq both fell by a whopping 1.46 percent and 3.07 percent, respectively, over fears that China is ...

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

JNJ beat Q4 estimates for both earnings and ... billion in aggregate option fees and milestone payments. The NYSE ARCA Pharmaceutical Index declined 1.6% in the past five trading sessions.

Pharmaceutical giant Johnson & Johnson grew its share prices by 4.14 percent to close at $152.89 apiece as investors took heart from an investment bank’s rating upgrade of the company.